Your browser doesn't support javascript.
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.
Ponzano, Marta; Schiavetti, Irene; Bovis, Francesca; Landi, Doriana; Carmisciano, Luca; De Rossi, Nicola; Cordioli, Cinzia; Moiola, Lucia; Radaelli, Marta; Immovilli, Paolo; Capobianco, Marco; Bragadin, Margherita Monti; Cocco, Eleonora; Scandellari, Cinzia; Cavalla, Paola; Pesci, Ilaria; Confalonieri, Paolo; Perini, Paola; Bergamaschi, Roberto; Inglese, Matilde; Petracca, Maria; Trojano, Maria; Tedeschi, Gioacchino; Comi, Giancarlo; Battaglia, Mario Alberto; Patti, Francesco; Fragoso, Yara Dadalti; Sen, Sedat; Siva, Aksel; Karabudak, Rana; Efendi, Husnu; Furlan, Roberto; Salvetti, Marco; Sormani, Maria Pia.
  • Ponzano M; Department of Health Sciences, University of Genoa, Genoa, Italy. Electronic address: ponzano.marta@gmail.com.
  • Schiavetti I; Department of Health Sciences, University of Genoa, Genoa, Italy.
  • Bovis F; Department of Health Sciences, University of Genoa, Genoa, Italy.
  • Landi D; Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
  • Carmisciano L; Department of Health Sciences, University of Genoa, Genoa, Italy.
  • De Rossi N; Centro Sclerosi Multipla ASST Spedali Civili di Brescia, Montichiari, Italy.
  • Cordioli C; Centro Sclerosi Multipla ASST Spedali Civili di Brescia, Montichiari, Italy.
  • Moiola L; Department of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Radaelli M; Department of Neurology and Multiple Sclerosis Center, ASST "Papa Giovanni XXIII", Bergamo, Italy.
  • Immovilli P; Multiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
  • Capobianco M; Regional Referral Multiple Sclerosis Centre, Department of Neurology, University Hospital San Luigi, Orbassano, Torino, Italy.
  • Bragadin MM; AISM Rehabilitation Center, Italian MS Society, Genoa, Italy.
  • Cocco E; Centro Sclerosi Multipla, ATS Sardegna, Cagliari, Italy.
  • Scandellari C; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, Bologna, Italy.
  • Cavalla P; MS Center, Department of Neuroscience, City of Health and Science University Hospital of Turin, Turin, Italy.
  • Pesci I; Centro SM UOC Neurologia, Fidenza, AUSL PR, Fidenza, Italy.
  • Confalonieri P; Multiple Sclerosis Centre, Neuroimmunology Department 'Carlo Besta' Neurological Institute, Milan, Italy.
  • Perini P; Department of Neurology Multiple Sclerosis Center, University of Padua, Padova, Italy.
  • Bergamaschi R; Multiple Sclerosis Research Center, IRCCS Mondino Foundation, Pavia, Italy.
  • Inglese M; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Petracca M; Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy; Department of Human Neurosciences, Sapienza University, Rome, Italy.
  • Trojano M; Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.
  • Tedeschi G; Department of Advanced Medical and Surgical Sciences, University of Campania "L. Vanvitelli", Naples, Italy.
  • Comi G; Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milano.
  • Battaglia MA; Research Department, Italian Multiple Sclerosis Foundation, Genoa, Italy; Department of Life Sciences, University of Siena, Italy.
  • Patti F; Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania; Centro Sclerosi Multipla, Policlinico Catania, University of Catania.
  • Fragoso YD; Post Graduate Studies, Universidade Metropolitana de Santos, Santos, SP, Brazil.
  • Sen S; Ondokuz Mayis University School of Medicine Samsun, Turkey.
  • Siva A; Istanbul University Cerrahpasa School of Medicine Istanbul, Turkey.
  • Karabudak R; Hacettepe University School of Medicine Ankara, Turkey.
  • Efendi H; Kocaeli University School of Medicine Kocaeli, Turkey.
  • Furlan R; Division of Neuroscience, Italian Neuroimmunology Association-AINI, IRCCS Ospedale San Raffaele, Institute of Experimental Neurology, Milano, Italy.
  • Salvetti M; Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy; Unit of Neurology, IRCCS Neuromed, Pozzilli, Isernia, Italy.
  • Sormani MP; Department of Health Sciences, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Mult Scler Relat Disord ; 63: 103909, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1867612
ABSTRACT

BACKGROUND:

Many risk factors for the development of severe forms of Covid-19 have been identified, some applying to the general population and others specific to Multiple Sclerosis (MS) patients. However, a score for quantifying the individual risk of severe Covid-19 in patients with MS is not available. The aim of this study was to construct such score and to evaluate its performance.

METHODS:

Data on patients with MS infected with Covid-19 in Italy, Turkey and South America were extracted from the Musc-19 platform. After imputation of missing values, data were separated into training data set (70%) and validation data set (30%). Univariable logistic regression models were performed in the training dataset to identify the main risk factors to be included in the multivariable logistic regression analyses. To select the most relevant variables we applied three different approaches (1) multivariable stepwise, (2) Lasso regression, (3) Bayesian model averaging. Three scores were defined as the linear combination of the coefficients estimated in the models multiplied by the corresponding value of the variables and higher scores were associated to higher risk of severe Covid-19 course. The performances of the three scores were compared in the validation dataset based on the area under the ROC curve (AUC) and an optimal cut-off was calculated in the training dataset for the score with the best performance. The probability of showing a severe Covid-19 course was calculated based on the score with the best performance.

RESULTS:

3852 patients were included in the study (2696 in the training dataset and 1156 in the validation data set). 17% of the patients required hospitalization and risk factors for severe Covid-19 course were older age, male sex, living in Turkey or South America instead of living in Italy, presence of comorbidities, progressive MS, longer disease duration, higher Expanded Disability Status Scale, Methylprednisolone use and anti-CD20 treatment. The score with the best performance was the one derived using the Lasso selection approach (AUC= 0.72) and it was built with the following variables age, sex, country, BMI, presence of comorbidities, EDSS, methylprednisolone use, treatment. An excel spreadsheet to calculate the score and the probability of severe Covid-19 is available at the following link https//osf.io/ac47u/?view_only=691814d57b564a34b3596e4fcdcf8580.

CONCLUSIONS:

The originality of this study consists in building a useful tool to quantify the individual risk for Covid-19 severity based on patient's characteristics. Due to the modest predictive ability and to the need of external validation, this tool is not ready for being fully used in clinical practice to make important decisions or interventions. However, it can be used as an additional instrument to identify high-risk patients and persuade them to take important measures to prevent Covid-19 infection (i.e. getting vaccinated against Covid-19, adhering to social distancing, and using of personal protection equipment).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans / Male Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans / Male Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article